A treatment tested for early-stage breast cancer appears to reduce the risk of recurrence by 25%. The treatment, ribociclib, is developed by Novartis against the most common type of breast cancer.
More than 2 million breast cancers are diagnosed each year worldwide, and the disease causes more than 600,000 deaths per year. Most diagnoses are made at an early stage, but one-third of patients with stage 2 breast cancer will have a recurrence, an oncologist says.